



Make Chemo Safe

Extend the lives of late stage cancer patients by eliminating the severe and deadly side effects of Chemotherapy

Chemotherapy Research Institute

MakeChemoSafe.com

info@MakeChemoSafe.com

RESEARCH SCOPE ■ OVERVIEW OF THE RESEARCH WORK TO BE COMPLETED IN THE LABORATORY

1

STRUCTURED RESEARCH PROTOCOL

CONDUCT GENETIC AND EPIGENETIC TASKS TO IDENTIFY TARGETS

2

DEVELOP AGONISTS/ANTAGONISTS FOR CONFIRMED TARGETS

3

CONDUCT TEST TO IDENTIFY MULTIPLE PATHWAYS TO THE TARGETS

4

TEST AGONISTS/ANTAGONIST ON ZEBRA FISH AND CANCER INFECTED MICE

5

CONDUCT ELECTRO/MAGNETIC CELL TEST

6

DEVELOP FREQUENCIES FOR MAXIMUM POROSITY

7

PROOF REPORT

Overview of the principal research tasks that will be undertaken

The principal line of research focuses on two things. First, to get the Chemotherapy through the blood stream in a benign state with a "Chemo Packet" to eliminate the side effects on the body, and second to get the "Chemo Packet" into all cancer cells, where it is then activated killing the cancer cells. This approach has the added benefit of addressing the limitations of traditional Chemotherapy which deals only with fast growing cells leaving slow growing stem cells in place thereby risking a recurrence.

The first part builds upon the groundbreaking work on a "Chemo Packet" made up of Thapsigargin together with an activation "pin", a 5-amino-acid-long peptide that can be pulled only by an enzyme, called PSMA, found on the surface of blood vessels that feed cancer. Only upon contact with the PSMA will the Thapsigargin be released.

This second part of the research advances the groundbreaking work performed by Professor William Halperin, a Board Member of the Institute. This work destabilizes the cancer cell to make it more porous enabling it to receive the Chemotherapy more effectively. This is achieved using technology to alter the magnetic characteristics produced by intracellular particles. Comparisons have been made of the magnetic susceptibility in tissue containing intracellular particles with respect to control tissue. Details of the control tests result will be published in due course.

Support CRI and Help Save Potentially Millions of Lives at No Cost To You

Chemotherapy Research Institute is a registered charity and an approved 501(c)3 for tax purposes

BOARD
OVER/



Make Chemo Safe

Extend the lives of late stage cancer patients by eliminating the severe and deadly side effects of Chemotherapy

Chemotherapy Research Institute

MakeChemoSafe.com

info@MakeChemoSafe.com

BOARD MEMBERS ■ GUIDING THE RESEARCH WORK TO BE COMPLETED IN THE LABORATORY

David Goddard MD

DR. GODDARD, WITH OVER 46 YEARS IN MEDICINE, IS CLINICAL PROFESSOR OF MEDICINE AT NYU SCHOOL OF MEDICINE. A RESEARCH FELLOWSHIP, THE ARTHRITIS AND RHEUMATISM COUNCIL OF THE UNITED KINGDOM, RESEARCHER AT PROFESSOR JOHN HOLBOROW'S LABORATORY STUDYING NEUTROPHIL FUNCTION IN RHEUMATOID ARTHRITIS, A DOCTORATE IN MEDICINE FROM THE UNIVERSITY OF LONDON, A FELLOWSHIP IN RHEUMATOLOGY AT CHARING CROSS AND WESTMINSTER HOSPITALS IN LONDON, POSITIONS AT ALBERT EINSTEIN MEDICAL CENTER AND TEMPLE UNIVERSITY, PHILADELPHIA WHERE HE DIRECTED THE RHEUMATIC DISEASES RESEARCH LABORATORIES, ASSOCIATE CHIEF OF RHEUMATOLOGY AT WINTHROP UNIVERSITY HOSPITAL, CHIEF OF RHEUMATOLOGY AT LONG ISLAND COLLEGE HOSPITAL, AND PROFESSOR OF CLINICAL MEDICINE AT SUNY HSC. HE CURRENTLY SERVES AS MEDICAL DIRECTOR FOR NYU AMBULATORY CARE AT BROOKLYN HEIGHTS AND COBBLE HILL, BROOKLYN, NEW YORK. HE SERVES AS A MEMBER OF THE NYU INSTITUTIONAL REVIEW BOARD. HE IS A FELLOW OF THE AMERICAN COLLEGE OF PHYSICIANS.

John N. Allan MD

DR ALLAN SPECIALIZING IN LYMPHOMA, CONDUCTING RESEARCH INTO CLL AND RICHTER'S SYNDROME AS WELL AS LYMPHOMA. HE IS AN ASSISTANT PROFESSOR IN HEMATOLOGY AND ONCOLOGY, A FELLOW, WEILL CORNELL MEDICAL COLLEGE, A MEMBER OF THE CLL RESEARCH CENTER, AND HAS MORE THAN 38 RESEARCH PUBLICATIONS TO HIS CREDIT, AND HAS OVER 20 PEER REVIEWED EXTRACTS

Abraham Chachoua MD

DR ABRAHAM CHACHOUA, WITH OVER 30 YEARS IN MEDICINE, PROFESSOR OF ONCOLOGY, DEPARTMENT OF MEDICINE AT NYU GROSSMAN SCHOOL OF MEDICINE, AND PROFESSOR, DEPARTMENT OF UROLOGY AT NYU GROSSMAN SCHOOL OF MEDICINE. HE SPECIALIZES IN THE TREATMENT OF ADVANCED THORACIC CANCER, CONTINUES TO FOCUS ON THE TREATMENT OF CANCERS OF THE LUNG AND CHEST, AND IS CURRENTLY CONDUCTING IMPORTANT IMMUNOLOGY RESEARCH. HE HAS A FELLOWSHIP AT ALFRED HOSPITAL IN HEMATOLOGY/ONCOLOGY, IS THE RECIPIENT OF THE AMERICAN CANCER SOCIETY CAREER DEVELOPMENT AWARD, AND HAS OVER 90 PUBLICATIONS TO HIS CREDIT.

Professor William Halperin PHD

PROFESSOR HALPERIN, AN ORRINGTON LUNT PROFESSOR, IS A DISTINGUISHED PHYSICIST WITH A CAREER SPANNING MORE THAN 45 YEARS. HE IS THE RECIPIENT OF THE PRESTIGIOUS INTERNATIONAL FRITZ LONDON MEMORIAL PRIZE IN PHYSICS AND HAS OVER 50 HONORS AND APPOINTMENTS. THESE INCLUDE CHAIR, DEPARTMENT OF PHYSICS AND ASTRONOMY (NU), DIRECTOR, INTEGRATED SCIENCE PROGRAM (NU), PROFESSOR, NORTHWESTERN UNIVERSITY, CHAIR, DIVISION OF CONDENSED MATTER PHYSICS, AMERICAN PHYSICAL SOCIETY, AND CHAIR, C5 COMMISSION, INTERNATIONAL UNION OF PURE AND APPLIED PHYSICS. HE IS A LIFE MEMBER AND FELLOW, AMERICAN PHYSICAL SOCIETY, FELLOW OF THE INSTITUTE OF PHYSICS (UK) AND MEMBER, AMPERE SOCIETY.

Yelena Novik MD

DR YELENA NOVIK HAS BEEN A PHYSICIAN FOR OVER 33 YEARS, AND SPECIALIZES IN BREAST CANCER. DR NOVIK HAS A FELLOWSHIP AT MONTEFIORE MEDICAL CENTER, HEMATOLOGY & ONCOLOGY, IS A FELLOW AT THE AMERICAN COLLEGE OF PHYSICIANS, IS CHAIR OF A SPECIALIZED NYU SCHOOL OF MEDICINE'S INSTITUTIONAL REVIEW BOARD, AND IS CURRENTLY ASSOCIATE PROFESSOR OF CLINICAL MEDICINE, NYU SCHOOL OF MEDICINE. SHE IS ALSO CERTIFIED AS A FDA CLINICAL INVESTIGATOR TRAINING, A PAST CHAIR, CANCER COMMITTEE, BELVUE HOSPITAL, CHAIR, CANCER CLINICAL INVESTIGATION COMMITTEE, PERLMUTTER CANCER CENTER, PAST MEDICAL DIRECTOR, CLINICAL TRIALS, NYU CANCER INSTITUTE. AND CURRENTLY PARTICIPATES IN CLINICAL TRIALS AT PERLMUTTER CANCER CENTER.

Professor Michael Robbins

MR ROBBINS HAS OVER 25 YEARS EXPERIENCE IN THE INVESTMENT MANAGEMENT OF LARGE PORTFOLIOS RANGING BETWEEN \$10 BILLION AND \$100 BILLION FOR MAJOR INSTITUTIONS ALL OVER THE WORLDS. HE IS A PROFESSOR AT COLUMBIA UNIVERSITY TEACHING AI IN PORTFOLIO MANAGEMENT. HE IS ALSO APPLYING AI TO CANCER RESEARCH IN SEVERAL PROGRAMS INCLUDING COLLABORATIONS WITH FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH. HE QUALIFIED AS A NUCLEAR ENGINEER, SPECIALIZING IN THE MEDICAL AND MILITARY APPLICATIONS OF ELECTROMAGNETIC RADIATION.

Dr Ann Hohenhaus

DR HOHENHAUS IS A DIPLOMATE, AMERICAN COLLEGE OF VETERINARY INTERNAL MEDICINE (ONCOLOGY), A DIPLOMATE, AMERICAN COLLEGE OF VETERINARY INTERNAL MEDICINE (SMALL ANIMAL INTERNAL MEDICINE), AND A DVM FROM CORNELL UNIVERSITY, AND IS CURRENTLY INVESTIGATING IMMUNOTHERAPY FOR HEMANGIOSARCOMA IN DOGS.

Dr Joseph Impellizeri

DR IMPELLIZERI, WITH A VETERINARY CAREER SPANNING OVER 25 YEARS, IS A DIPLOMATE, AMERICAN COLLEGE OF VETERINARY INTERNAL MEDICINE (ONCOLOGY), A MEMBER, ROYAL COLLEGE OF VETERINARY SURGEONS, A VISITING SCHOLAR, BIOLOGY, AT VASSAR COLLEGE, DIRECTOR, BARRYMORE CENTER FOR ADVANCED CANCER THERAPEUTICS FOCUSING ON CANCER IMMUNOTHERAPY, ELECTROCHEMOTHERAPY, AND ELECTROGENETTRANSFER, AND DIRECTOR- BONE MARROW TRANSPLANT UNA —VETERINARY SPECIALTY CENTER OF THE HUDSON VALLEY. HE HAS BEEN INVOLVED IN MANY GROUNDBREAKING RESEARCH

Support CRI and Help Save Potentially Millions of Lives at No Cost To You

To see the full biographies of the Board, please visit our web site at <https://MakeChemoSafe.com/minds.html>